Outlook Therapeutics Inc
Company Profile
Business description
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Contact
111 S. Wood Avenue
Suite 100
IselinNJ08852
USAT: +1 609 619-3990
E: LawrenceKenyon@outlooktherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 September 2025
Employees
23
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,624.90 | 6.60 | -0.08% |
| CAC 40 | 7,788.10 | 38.69 | -0.49% |
| DAX 40 | 24,038.19 | 188.30 | -0.78% |
| Dow JONES (US) | 42,098.70 | 244.95 | -0.58% |
| FTSE 100 | 8,726.01 | 52.04 | -0.59% |
| HKSE | 23,258.31 | 123.68 | -0.53% |
| NASDAQ | 19,100.94 | 98.22 | -0.51% |
| Nikkei 225 | 37,722.40 | 1.71 | -0.00% |
| NZX 50 Index | 12,362.26 | 220.07 | -1.75% |
| S&P 500 | 5,888.55 | 32.99 | -0.56% |
| S&P/ASX 200 | 8,396.90 | 10.70 | -0.13% |
| SSE Composite Index | 3,339.93 | 0.76 | -0.02% |